Data streams
Multiple
Actigraphy · PRO · Cognitive tasks
Population challenge
Cognitive
Impairment affects compliance
Caregiver role
Critical
eObsRO often required
CNS Digital Endpoint Model
Assess · Monitor · Support · Protect
Digital endpoints in CNS trials are not just wearables and eDiaries applied to a different disease area. The population characteristics, assessment complexity, and data requirements create a fundamentally different compliance challenge.
Patients in Alzheimer's, Parkinson's, major depression, schizophrenia, and other CNS studies are managing conditions that directly affect their ability to engage with digital assessment tools. Cognitive impairment makes tablet-based cognitive batteries harder to complete consistently. Mood variability in psychiatric studies means patient engagement is unpredictable. Fatigue and motor impairment in Parkinson's affect the quality of active tasks like typing or tapping.
The result is that digital endpoint data in CNS trials is often noisier, more incomplete, and more caregivedependent than the same data in metabolic or respiratory studies. Building for this is not optional.
See also: CNS Trials · Digital Biomarkers
These are the operational conditions that determine whether digital CNS endpoints generate usable data — or produce a compliance report that looks acceptable while the data is degraded.
Many CNS patients cannot complete digital assessments independently throughout the course of a study. eObsRO and caregiver-guided completion workflows need to be built into the platform from the start — not added when compliance problems emerge.
Digital cognitive batteries designed for research settings may be too complex for at-home, unsupervised completion by cognitively impaired patients. Platform design needs to account for the population, not just the scientific requirements of the instrument.
Compliance in CNS studies is more variable than in most disease areas. A patient who was completing tasks reliably in week four may stop entirely in week six due to symptom fluctuation. Real-time monitoring with a short response window is essential to catch and address these gaps.
Actigraphy-based sleep endpoints are common in CNS trials but generate usable data only when worn consistently during sleep hours. Monitoring wear compliance specifically during the target measurement window — not just average daily wear — is required.
In psychiatric studies, compliance correlates with symptom state. Patients who are more symptomatic are less compliant — which creates a systematic missing data problem precisely when the study is most interested in capturing their state. Proactive outreach during symptom fluctuation windows is the intervention that protects this data.
CNS sites need deeper training on digital endpoint tools than most. The patient population requires adapted support, and sites that are not equipped to answer patient and caregiver questions create compliance failures at the first friction point.
Actigraphy uses wrist-worn accelerometers to measure movement and rest patterns, providing an objective proxy for sleep quality, daytime activity, and circadian rhythm. In CNS trials, it supplements PRO sleep diaries and provides data between clinic visits.
Digital cognitive batteries can complement and partially reduce reliance on clinical rater assessments, but full replacement requires regulatory qualification of the digital endpoint. Many CNS sponsors use digital tools to enrich the data picture rather than replace established instruments.
Caregiver involvement can improve completion rates but may introduce reporter bias if workflows are not clearly defined. eObsRO platforms with defined caregiver roles, clear instructions, and auditable completion records help maintain data integrity while enabling necessary caregiver support.
Delve supports CNS trials with eCOA, wearables, actigraphy, and caregiver-adapted workflows — plus the compliance monitoring and concierge support that cognitively impaired populations require.
Talk About Your CNS Study